drugset / Trial / NCT06803030

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

NCT06803030

Phase 3 Recruiting 189 enrolled Bir Hospital Nepal Health Research Council · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

Timeline

Start
2025-08-30
Primary completion
2025-12-01
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified 25 mg
Comparator Solifenacin Small molecule 5 mg
Comparator Tamsulosin Other / unclassified 0.4 mg

Indications

No indication recorded.